Stay updated with breaking news from Eric Althoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
East Hartford’s Construction Solutions Group LLC has been tapped by the Torrington City Council to oversee buildout of a new combination middle and high school.
School Construction News By Eric Althoff LEXINGTON, Ky.—The University of Kentucky’s College of Design has selected the Studio Gang as designer for the Reynolds Building, an early-20th-century building that was once a tobacco warehouse, for new use by the college. The university has had its sights set on the building for a half-century, as its convenient location will allow for the school’s design courses and studio space to grow in the years to come. Furthermore, by maintaining the historic building’s architectural motifs, students in the design school will be able to observe earli...
(ofatumumab) Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that provides the flexibility of self-administration for adults with RMS. It is an anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly injection, delivered subcutaneously 1,3. Initial doses of Kesimpta are given at Weeks 0, 1 and 2, with the first injection performed under the guidance of a healthcare professional. As shown in preclinical studies, Kesimpta is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion 8. The selective mech...
(ofatumumab) Kesimpta is a targeted, precisely dosed and delivered B-cell therapy that provides the flexibility of self-administration for adults with RMS. It is an anti-CD20 monoclonal antibody (mAb) self-administered by a once-monthly injection, delivered subcutaneously 1,3. Initial doses of Kesimpta are given at Weeks 0, 1 and 2, with the first injection performed under the guidance of a healthcare professional. As shown in preclinical studies, Kesimpta is thought to work by binding to a distinct epitope on the CD20 molecule inducing potent B-cell lysis and depletion 8. The selective mech...
ng Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis (TB). 1 Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world. Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by t...